Dextromethorphan and dextrorphan in rats: Common antitussives - Different behavioural profiles

Fundamental and Clinical Pharmacology

Volumn 12, Issue 5, 1998, Pages 526-537

  Dematteis, M ^a,b   Lallement, G ^a   Mallaret, M ^b  

^a CENTRE DE RECHERCHES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Dextromethorphan; Dextrorphan; Learning; Memory; Motor activity; Phencyclidine

Indexed keywords

ANTITUSSIVE AGENT; DEXTROMETHORPHAN; DEXTRORPHAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; QUINIDINE;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ATAXIA; BEHAVIOR DISORDER; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNING DISORDER; LOCOMOTION; MALE; MAZE TEST; MOTOR ACTIVITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RECALL; SCORING SYSTEM; SPATIAL MEMORY; STEREOTYPY; WORKING MEMORY;

EID: 0032407477     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00982.x     Document Type: Article

References (63)

1. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke 1995 ; 26 : 254-8
2. Albers GW, Saenz RE, Moses Jr JA. Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin Neuropharmacol 1992 ; 15 : 509-14
3. Amano M, Yamada K, Matsuno K, Nabeshima T. Neuropharmacological effects of sigma receptor ligands: anxiolytic, antiamnesic and neuroprotective effects. Nihon Shinkei Seishin Yakurigaku Zasshi 1996 ; 16 : 73-84
4. Askmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stålberg E, Wuopio R. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993 ; 56 : 197-200
5. Bane A, Rojas D, Indermaur K, Bennett T, Avery D. Adverse effects of dextromethorphan on the spatial learning of rats in the Morris water maze. Eur J Pharmacol 1996 ; 302 : 7-12
6. Bem JL, Peck R. Dextromethorphan. An overview of safety issues. Drug Suf 1992 ; 1 : 190-9
7. Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993 ; 361 : 31-9
8. Block F, Schwarz M. Dextromethorphan reduces functional deficits and neuronal damage after global ischemia in rats. Brain Res 1996; 741 : 153-9
9. Bonuccelli U, Del Dotto P, Piccini P, Behge F, Corsini GU, Muratorio A. Dextromethorphan and parkinsonism. Lancet 1992 ; 340 : 53
10. Brandeis R, Brandys Y, Yehuda S. The use of the Morris water maze in the study of memory and learning, Int J Neurosci 1989 ; 48 : 29-69
11. Bubser M, Zadow B, Kronthaler UO, Felsheim U, Rückert NGH, Schmidt WJ. Behavioural pharmacology of the non-competitive NMDA antagonists dextrorphan and ADCI: relations between locomotor stimulation, anticataleptic potential and forebrain dopamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 1997 ; 355 : 767-73
12. 3H]dextromethorphan in guinea pig brain: allosteric enhancement by ropizine. J Neurosci Res 1989; 24 : 311-28
13. Carter AJ. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination. J Pharmacol Exp Ther 1994 ; 269 : 573-80
14. Contreras PC, Rice KC, Jacobson AE, O'Donohue TL. Stereotyped behavior correlates better than ataxia with phencyclidine-receptor interactions. Eur J Pharmacol 1986 ; 121 : 9-18
15. Danysz W, Essmann U, Bresink I, Wilke R. Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994 ; 48 : 111-8
16. Dematteis M, Mallaret M, Baubichon D, Pernot-Marino I, Lallement G. Evaluation of dextromethorphan and dextrorphan as a preventive treatment of soman toxicity in mice. Neurosci Lett 1997 ; 234 : 91-4
17. Diana G, Sagratella S. Different capability of N-Methyl-D-Aspartate antagonists to affect locomotor/exploratory activity of mice in a computerized on-line open field test. Pharmacol Biochem Behav 1994 ; 48 : 291-5
18. Fleming PM. Dependence on dextromethorphan hydrobromide. Br Med J 1986 ; 293 : 597
19. Funck-Brentano C, Thomas G, Jacqz-Aigrain E, Poirier JM, Simon T, Bereziat G et al. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans. J Pharmacol Exp Ther 1992 ; 263 : 780-6
20. Gavend M, Mallaret M, Dematteis M, Baragatti G. Discriminative stimulus properties of dextromethorphan in rats. Biomed Pharmacother 1995 ; 49 : 456-64
21. Hamosh A, McDonald JW, Valle D, Francornano CA, Niedermeyer E, Johnston MV. Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 1992 ; 121 : 131-5
22. Himori N, Tanaka Y, Kurasawa M, Mishima K, Akaike N, Imai M et al. Dextrorphan attenuates the behavioral consequences of ischemia and the biochemical consequences of anoxia: possible role of N-methyl-D-aspartate receptor antagonism and ATP replenishing action in its cerebroprotecting profile. Psychopharmacology 1993 ; 111 : 153-62
23. Holtzman SG. Phencyclidine-like discriminative effects of opioids in the rat. J Pharmacol Exp Ther 1980 ; 214 : 614-9
24. Isbell H, Fraser HF. Actions and addiction liabilities of dromoran derivatives in man. J Pharmacol Exp Ther 1953 ; 107 : 524-30
25. Junien JL, Leonard BE. Drugs acting on sigma and phencyclidine receptors: a review of their nature, function and possible therapeutic importance. Clin Neuropharmacol 1989 ; 12 : 353-74
26. Klein M, Musacchio JM. High-affinity dextromethorphan and (+)-3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine binding sites in rat brain. Allosteric effects of ropizine. J Pharmacol Exp Ther 1992; 260: 990-9
27. Klette KL, DeCoster MA, Moreton JE, Tortella FC. Role of calcium in sigma-mediated neuroprotection in rat primary cortical neurons. Brain Res 1995 ; 704 : 31-41
28. Koek W, Woods JH, Ornstein P. A simple and rapid method for assessing similarities among directly observable behavioral effects of drugs: PCP-like effects of 2-amino-5-phosphonovalerate in rats. Psychopharmacolagy 1987 ; 91 : 297-304
29. Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 1993 ; 16 : 527-32
30. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994 ; 330 : 613-22
31. Löscher W, Hönack D. Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. Eur J Pharmacol 1993 ; 238 : 191-200
32. 1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur J Pharmacol 1993 ; 242 : 99-104
33. Maurice T, Hiramatsu M, Itoh J, Kameyama T, Hasegawa T, Nabeshima T. Behavioral evidence for a modulating role of sigma ligands in memory processes. I. Attenuation of dizocilpine (MK801)-induced amnesia. Brain Res 1994 ; 647 : 44-56
34. McNamara RK, Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 1993 ; 18 : 33-49
35. Meoni P, Tortella FC, Bowery NG. An autoradiographic study of dextromethorphan high-affinity binding sites in rat brain: sodium-dependency and colocalization with paroxetine. Br J Pharmacol 1997 ; 120 : 1255-62
36. Mitchell D, Maren S, Hwang R. The effects of hippocampal lesions on two neotic choice tasks. Psychobiology 1993 ; 21 : 193-202
37. Moreau JL, Pieri L, Prud'hon B. Convulsions induced by centrally administered NMDA in mice: effects of NMDA antagonists, benzodiazepines, minor tranquilizers and anticonvulsants. Br J Pharmacol 1989 ; 98 : 1050-4
38. Morris RGM. An attempt to dissociate 'spatial-mapping' and 'working-memory' theories of hippocampal function. In: Siefert W, ed. Molecular, Cellular and Behavioural Neurobiology of the Hippocampus. London: Academic Press; 1983. p. 405-32
39. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984 ; 11 : 47-60
40. Murata S, Kawasaki K. Common and uncommon behavioural effects of antagonists for different modulatory sites in the NMDA receptor/channel complex. Eur J Pharmacol 1993 ; 239 : 9-15
41. 3H]dextrorphan recognition site of the NMDA-operated cation channels mediates the anticonvulsant actions of dextrorotatory opioids and phencyclidine. In: Kamenka JM, Domino EF, eds. Multiple Sigma and PCP Receptor Ligands: Mechanisms for Neuromodulation and Neuroprotection? Ann Arbor: NPP Books; 1992. p 695-713
42. Netzer R, Pflimlin P, Trube G. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical currents. Eur J Pharmacol 1993 ; 238 : 209-16
43. Ohno M, Yamamoto T, Watanabe S. Effects of intrahippocampal injections of N-methyl-D-aspartate receptor antagonists and scopolamine on working and reference memory assessed in rats by a three-panel runway task. J Pharmacol Exp Ther 1992 ; 263 : 943-50
44. Okuyama S, Imagawa Y, Sakagawa T, Nakazato A, Yamaguchi K, Katoh M et al. NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dogs and monkeys. Life Sci 1994 ; 55 : 133-8
45. Ramachander G, Bapatla KR, Emele JF. Sex differences in plasma half-life of dextrorphan in rats administered dextromethorphan. J Pharm Sci 1978 ; 67 : 1326-7
46. Rückert NGH, Schmidt WJ. The sigma receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia. Eur J Pharmacol 1993 ; 233 : 261-7
47. Sanger DJ, Joly D. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice. Psychopharmacology 1991 ; 104 : 27-34
48. Schmitt B, Netzer R, Fanconi S, Baumann P, Boltshauser E. Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients. J Neurol Neurosurg Psychiatry 1994 ; 57 : 333-9
49. Schneider SM, Michelson EA, Boucek CD, Ilkhanipour K. Dextromethorphan poisoning reversed by Naloxone. Am J Emerg Med 1991 ; 9 : 237-8
50. Sierocinska J, Nikolaev E, Danysz W, Kaczmarek L. Dextrorphan blocks long-but not short-term memory in a passive avoidance task in rats. Eur J Pharmacol 1991 ; 205 : 109-11
51. Shaul WL, Wandell M, Robertson WO. Dextromethorphan toxicity: reversal by Naloxone. Pediatrics 1977 ; 59 : 117-9
52. Sturgeon RD, Fessier RG, Meltzer HY. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. Eur J Pharmacol 1979 ; 59 : 169-79
53. Székely JI, Sharpe LG, Jaffe JH. Induction of phencyclidine-like behavior in rats by dextrorphan but no dextromethorphan. Pharmacol Biochem Behav 1991 ; 40 : 381-6
54. Takahama K, Fukushima H, Isohama Y, Kai H, Miyata T. Inhibition of glycine currents by dextromethorphan in neurones dissociated from the guinea-pig nucleus tractus solitarii. Br J Pharmacol 1997 ; 120 : 690-4
55. Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989 ; 10 : 501-7
56. Tortella FC, Robles L, Witkin JM, Newman AH. Novel anticonvulsant analogs of dextromethorphan: Improved efficacy, potency, duration and side-effect profile. J Pharmacol Exp Ther 1994 ; 268 : 727-33
57. Walker J, Yatham LN. Benylin (dextromethorphan) abuse and mania. Br Med J 1993 ; 306 : 896
58. Whishaw IQ, Auer RN. Immediate and long-lasting effects of MK-801 on motor activity, spatial navigation in a swimming pool and EEG in the rat. Psychopharmacology 1989 ; 98 : 500-7
59. Willets J, Balster RL, Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 1990 ; 11 : 423-8
60. Wu D, Otton SV, Kalow W, Sellers EM. Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat. J Pharmacol Exp Ther 1995 ; 274 : 1431-7
61. Ylinen A, Pitkänen M, Sirviö J, Hartikainen T, Sivenius J, Koivisto E et al. The effects of NMDA receptor antagonists at anticonvulsive doses on the performance of rats in the water maze task. Eur J Pharmacol 1995 ; 274 : 159-65
62. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992 ; 51 : 647-55
63. Zhou GZ, Musacchio JM. Computer-assisted modeling of multiple dextromethorphan and sigma binding sites in guinea pig brain. Eur J Pharmacol Mol Pharmacol Sect 1991 ; 206 : 261-9